Support Education Research
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #680 | October 14, 2016  

Tracleer May Delay Onset of Pulmonary Arterial Hypertension (PAH) in Scleroderma Patients

blood-vessel-pah-m.jpgEarly treatment with Tracleer (bosentan) may delay the development of pulmonary arterial hypertension (PAH) in people with scleroderma, according to a study that compared patients who had never used this medicine with those taking it for digital ulcers.

Click here for more >>

15 Best Superfoods for Fall

fall-foods-superfruit-400x400.jpgThe weather is getting cooler (for most of us), but your produce choices are heating up!  These superfoods are either hitting their peak in the garden or can easily be found at your local farmers market or grocery store.

Click here for more >>

Video: Skin Care and Wound Management in Systemic Sclerosis

eletter1014.jpgWe are happy to announce that select videos from the 2016 National Conference are now available online.  In this session, Alexandria Crowe, R.N., helps patients understand what is happening to their skin as Systemic Sclerosis progresses. She also includes evidence-based therapies to consider.  This video and more can be found on our YouTube channel.  We will continue to post more videos as them become available.

Click here to watch the entire session >>

Clinical Trial Update

Reata Pharmaceuticals, Inc. Enrolls First Patient in Phase 3 CATALYST Trial of Bardoxolone Methyl in Connective Tissue Disease-Associated with Pulmonary Arterial Hypertension (CTD-PAH)

Reata Pharmaceuticals, Inc. has enrolled the first patient into its Phase 3 trial (CATALYST) to evaluate the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).

Click here to


Quick Links
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
2016 Instagram

Giving Tuesday
Actelion 2016 sponsor
2016 Bayer Logo
2016 Bronze National Sponsor Reata
2016 Gilead Silver Conference Sponsor
United Therapeutics Logo


Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2019 All rights reserved.